Scenario | Wolbachia (%) | Paediatric vaccination (%) | Cases (millions) | DALYs lost | Total costs (PP) ($millions) |
---|---|---|---|---|---|
Wolbachia cost (lower bounds) | 100 | 71 | 1.073 | 10,143 | 368.820 |
Vaccine cost −50% | 43 | 100 | 1.075 | 10,167 | 367.215 |
Unit cost profile [59] | 45 | 64 | 1.161 | 10,979 | 368.916 |
80% vaccine efficacy | 44 | 53 | 1.180 | 11,158 | 368.389 |
Societal perspective | 51 | 43 | 1.206 | 11,399 | 368.846 |
Vaccine coverage 70–100% | 22 | 70 | 1.216 | 11,500 | 368.680 |
50% vaccine efficacy | 69 | 33 | 1.221 | 11,540 | 368.630 |
Vaccine cost + 50% | 68 | 23 | 1.230 | 11,628 | 368.925 |
Wolbachia cost (upper bounds) | 21 | 41 | 1.326 | 12,531 | 366.220 |
5-year follow-up | 33 | 22 | 1.317 | 12,450 | 202.720 |